Vyzulta (Latanoprostene Bunod) Patent Expiration, LOE Window & CMS Spending
Vyzulta (Latanoprostene Bunod) by Bausch Health: FDA Orange Book core substance LOE 2029-02-21, 1 AB generics, $133.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bausch Health |
| FDA Application & Pathway | N207795 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2029-02-21 |
| Last Listed Patent or Exclusivity Date | 2029-02-21 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $133.8M |
| 2024 Medicare Part D Spend | $128.3M |
| 2024 Medicaid Spend | $5.5M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 19.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bausch Health / Bausch + Lomb FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBausch Health / Bausch + Lomb Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bausch Health / Bausch + Lomb 401(k) & Form 5500 Planerisa.meruai.co →